116,556 views
Obesity is a complex and multifactorial pathology that today affects a growing proportion of the world's population. With serious health consequences, such as type 2 diabetes and cardiovascular diseases, it represents a real challenge for healthcare systems. The arrival of new pharmacological molecules, such as semaglutide and tirzepatide, is changing the situation and confronting doctors with many questions. These treatments, alone or in combination, promise spectacular results, with an average weight loss of 15 to 20% of the initial weight. But these advances also raise crucial questions: • Obesity: a risk factor or a chronic disease in its own right? • What place for these treatments in a broader care pathway, in addition to or as an alternative to bariatric surgery? • What impacts on medical practices and the training of healthcare professionals? • The medico-economic issues: how to finance these innovative solutions and guarantee equitable access? To discuss this, we have the honor of welcoming a key figure on the subject: Professor Karine Clément, a leading figure in the field of nutrition and metabolic diseases. Guest: Professor Karine Clément, Professor of Nutrition at the Pitié-Salpêtrière Hospital and Sorbonne University, Paris Permanent Guest: Professor Jean-François Bergmann Moderator: Dr. Jean-François Lemoine